Extracorporeal Membrane Oxygenation

New data from the International Viral Infection and Respiratory Illness Universal Study Registry highlight variation in outcomes of patients with COVID-19 by type and combination of organ support therapy and age.

A protocol with extracorporeal membrane oxygenation-facilitated resuscitation improved survival in patients with out-of-hospital cardiac arrest vs. standard advanced cardiac life support, according to results of the ARREST trial.

Abiomed announced its compact cardiopulmonary bypass system received 510(k) clearance from the FDA.

Early outcomes of a single-center study demonstrate clinical benefit of extracorporeal membrane oxygenation support in patients with severe COVID-19, according to a study published in The Annals of Thoracic Surgery.

The Healio editors have compiled a list of the most-read pulmonology news published in August.

Two recently published studies report success with extracorporeal membrane oxygenation support in patients with acute respiratory distress syndrome associated with COVID-19.

Abiomed announced that the FDA has issued an emergency use authorization allowing its left-sided heart pumps to provide left ventricular unloading and support to certain patients with COVID-19.

Abiomed announced it has acquired Breethe, developer of an extracorporeal membrane oxygenation system, in an effort to better support patients with cardiogenic shock or other conditions which produce insufficient oxygen to the lungs.

The American Thoracic Society has released new guidance on how to approach treatment of COVID-19 during the global pandemic.

The FDA recently cleared the Novalung extracorporeal membrane oxygenation system — the first to be cleared for more than 6 hours of use as extracorporeal life support — for treatment of acute respiratory or cardiopulmonary failure, according to a press release from Fresenius Medical Care North America.